Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $90.43 Consensus PT from Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $93.75.

Several brokerages recently commented on ESTA. Mizuho boosted their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. BTIG Research reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Citigroup increased their price objective on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Finally, TD Cowen boosted their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research note on Monday.

Hedge Funds Weigh In On Establishment Labs

Institutional investors have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. increased its holdings in shares of Establishment Labs by 92.1% during the fourth quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Establishment Labs by 325.5% in the first quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock valued at $1,160,000 after acquiring an additional 15,624 shares during the last quarter. Union Square Park Capital Management LLC boosted its holdings in shares of Establishment Labs by 16.7% in the 1st quarter. Union Square Park Capital Management LLC now owns 105,000 shares of the company’s stock worth $5,962,000 after acquiring an additional 15,000 shares in the last quarter. AlTi Global Inc. acquired a new position in shares of Establishment Labs in the 1st quarter worth approximately $842,000. Finally, SG Americas Securities LLC grew its position in Establishment Labs by 134.3% during the 1st quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock worth $2,154,000 after acquiring an additional 21,742 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Up 2.0%

NASDAQ ESTA opened at $94.61 on Friday. Establishment Labs has a 1-year low of $33.35 and a 1-year high of $97.59. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -63.50 and a beta of 1.07. The stock’s 50 day moving average is $85.77 and its two-hundred day moving average is $73.97. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company’s quarterly revenue was up 44.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. Equities analysts forecast that Establishment Labs will post -1.07 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.